Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an...
Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer
Innovent Biologics, Inc. (HKG: 1801) announced first patient dosing in the pivotal Phase 3 HeriCare-Breast01 study...
Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) has entered a landmark licensing agreement with Madrigal...
Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
Novartis AG (NYSE: NVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope...
Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic partnership between its PPD clinical research business...
MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
Merck & Co. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has...
Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a...
Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced first patient dosing in a Phase Ib/II clinical study...
Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy
Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) has submitted its IPO prospectus to the Hong Kong Stock...
PANACRO Pharma Files Hong Kong IPO to Expand Digital Clinical Research Platform
PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd., a China-based clinical contract research organization (CRO), has submitted...
Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) has approved...
Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that trastuzumab rezetecan (SHR-A1811), its HER2-targeted antibody-drug...
Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) announced plans for a private placement of up to...
uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO
uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership...
Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
Newsoara BioPharma Co., Ltd. and vTv Therapeutics LLC have expanded their strategic collaboration, with Newsoara...
Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
Siemens Healthineers AG (ETR: SHL) and Northwestern Medicine have officially launched the first phase of a...
SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
SciClone Pharmaceuticals Inc. (HKG: 6600) announced that the National Medical Products Administration (NMPA) has accepted for...
Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB 500 million (USD 72.34 million)...